eligibility_summary
Adults ≥18 with relapsed/refractory myeloma (measurable per IMWG) after ≥2 lines incl lenalidomide, a PI, anti‑CD38, and BCMA therapy (elotuzumab ok if no PD, >6 mo). ECOG 0–1, able to swallow, adequate blood/organ function (CrCl ≥45) and cardiac status (LVEF ≥30, QTcF ≤470), contraception required. Exclude other plasma cell disorders, ≥G2 neuropathy, major cardio‑respiratory disease, active HBV/HIV/HCV, recent surgery/trials, drug interactions/allergy, absorption issues, or noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b single-arm trial testing elotuzumab + mezigdomide (CC‑92480) + dexamethasone in relapsed/refractory multiple myeloma after CD38- and BCMA-directed therapies. Elotuzumab: humanized IgG1 monoclonal antibody targeting SLAMF7 (CS1) on myeloma and NK cells, enhancing NK-cell–mediated ADCC and immune activation. Mezigdomide (CC‑92480): oral CELMoD (cereblon E3 ligase modulator) that binds CRBN to induce degradation of Ikaros (IKZF1) and Aiolos (IKZF3), causing myeloma cell death and boosting T/NK-cell function. Dexamethasone: corticosteroid with lymphocytotoxic and anti-inflammatory effects, synergistic in MM. Targeted cells/pathways: malignant plasma cells, SLAMF7 axis, CRBN–IKZF1/3 ubiquitin–proteasome pathway, NK- and T-cell activation. Primary aim: safety/tolerability, key efficacy endpoints include response, PFS/OS, and MRD negativity.